Literature DB >> 1510454

Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

S M Borcherding1, T L Bastian, T H Self, N Abou-Shala, B W LeDuc, R L Lalonde.   

Abstract

The effects of two short-term chemoprophylaxis regimens of rifampin (2 or 4 days) on oxidative metabolism were investigated in 14 healthy subjects. Seven subjects received 600 mg of rifampin twice daily on study days 6 and 7 (group A), and seven subjects received 600 mg of rifampin once daily on days 4, 5, 6, and 7 (group B). Antipyrine (18 mg/kg of body weight) was administered orally on days 1, 8, and 15. Short-term rifampin regimens increased oral clearance of antipyrine in both groups compared with the baseline value (P less than 0.05), and group B displayed a larger percent increase over the baseline value than group A did (70.5 +/- 14.3 versus 33.1 +/- 18.1; P less than 0.05). The partial metabolic clearance (CLM) of antipyrine to 3-hydroxymethylantipyrine (HMA) on day 8 increased 71 and 108% for regimens A and B, respectively (P less than 0.05 for both). The corresponding increases in CLM to norantipyrine (NORA) were 57 and 98% (P less than 0.05 for both). CLM to 4-hydroxyantipyrine (OHA) on day 8 increased 64% for regimen A (P = 0.08) and 97% for regimen B (P less than 0.05) compared with the baseline. Although CLM to HMA and OHA on day 15 remained greater than 50% over the baseline with both regimens, CLM to NORA on day 15 was less than 25% over the baseline with both regimens. Thus, both short-term rifampin chemoprophylaxis regimens increased antipyrine clearance for at least 1 week. The increase tended to be higher with the 4-day regimen. The pattern observed for the CLMS suggests that more than one P-450 enzyme is affected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510454      PMCID: PMC191619          DOI: 10.1128/AAC.36.7.1553

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Immunizations, immunoprophylaxis, and chemoprophylaxis to prevent selected infections. US Preventive Services Task Force.

Authors:  F M LaForce
Journal:  JAMA       Date:  1987-05-08       Impact factor: 56.272

2.  Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

Authors:  E E Ohnhaus; A M Breckenridge; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Interaction of chloramphenicol and rifampin.

Authors:  H W Kelly; R C Couch; R L Davis; A H Cushing; R Knott
Journal:  J Pediatr       Date:  1988-05       Impact factor: 4.406

4.  Simultaneous administration of multiple model substrates to assess hepatic drug clearance.

Authors:  W R Crom; S L Webster; L Bobo; M E Teresi; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1987-06       Impact factor: 6.875

5.  Effect of rifampin on chloramphenicol levels.

Authors:  C G Prober
Journal:  N Engl J Med       Date:  1985-03-21       Impact factor: 91.245

6.  Enzyme induction and beta-adrenergic receptor blocking drugs.

Authors:  R A Branch; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

8.  Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.

Authors:  M W Teunissen; L G De Leede; J K Boeijinga; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

9.  The antagonistic effect of rifampin upon cyclosporine bioavailability.

Authors:  D Van Buren; C A Wideman; M Ried; S Gibbons; C T Van Buren; M Jarowenko; S M Flechner; O H Frazier; D A Cooley; B D Kahan
Journal:  Transplant Proc       Date:  1984-12       Impact factor: 1.066

10.  Update on rifampin drug interactions.

Authors:  A M Baciewicz; T H Self; W B Bekemeyer
Journal:  Arch Intern Med       Date:  1987-03
View more
  4 in total

1.  Allergy associated with ciprofloxacin.

Authors:  P Burke; S R Burne
Journal:  BMJ       Date:  2000-03-11

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 3.  Rifampin-accompanied antibiotic regimens in the treatment of prosthetic joint infections: a frequentist and Bayesian meta-analysis of current evidence.

Authors:  Ozlem Aydın; Pinar Ergen; Burak Ozturan; Korhan Ozkan; Ferhat Arslan; Haluk Vahaboglu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-30       Impact factor: 3.267

Review 4.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.